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Previewsamong the broader set of FGFs tested (1,
2, 9, and 10), did not demonstrate in vivo
glycemic efficacy in Suh et al. (2014).
FGF2 is almost as promiscuous as FGF1
in binding several FGFR isoforms and is
identical in its in vitro potency at the
FGFR1 when compared to FGF1 (Ornitz
et al., 1996). Consequently, in view of the
purported mechanism of FGF1 action
in vivo, it is unexpected that FGF2 would
not show a comparable level of efficacy.
Further pursuit of this paradox might
shed light on the purported mechanism
of FGF1 action and assist in designing
optimal clinical candidates.
Sowe have come full circle through four
decades of FGF research to a point where
we now have experimental evidence
validating the physiological role of FGF1
in metabolism to complement its more
established role as an anabolic agent.
The observation that FGF1 improves gly-
cemia without lipid, weight, or bone loss
is curious and distinguishes it from
FGF21 pharmacology. From a transla-tional perspective, Suh et al. provide initial
direction in optimization of native FGF1
for potential therapeutic use. Subsequent
refinement will surely benchmark against
FGF21, which has provided evidence of
clinical efficacy consistent with preclinical
observations, yet failed to offer a robust
glucose-lowering effect (Kharitonenkov
and Adams, 2014). It has taken four de-
cades to discover the metabolic activity
of FGF1, which, in a broader context, illus-
trates the commitment necessary to
biologically validate novel proteins. This
newly observed function provides a rea-
son to believe that breakthrough therapy
in adult-onset diabetes may be within
our reach.REFERENCES
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Reinduction of fetal gene expression is characteristic of the failing adult heart. Han et al. (2014) demonstrate
that a novel cluster of long noncoding RNAs, Myheart, protects the heart from pathological hypertrophy,
involving a negative-feedback molecular circuit with the epigenetic Brg1 complex to inhibit fetal-gene
reactivation.Human hearts are capable of undergo-
ing remarkable cardiac remodeling in
response to various environmental stim-
uli. Cardiac hypertrophy is one of the
primary responses of the heart to patho-
physiological stress. While physiological
hypertrophy enhances cardiac perfor-
mance to match physiological demands,
pathological hypertrophy results in a
decrease in cardiac function, accompa-
nied by reinduction of the fetal gene pro-
gram and increased fibrosis, representinga maladaptive response to pathological
stress/stimuli, which often progresses to
heart failure if prolonged (Ahmad et al.,
2005; Hill and Olson, 2008). Two myosin
heavy-chain genes, Myh6 and Myh7,
which encode the a- and b-MHC contrac-
tile proteins, respectively, are expressed
in mammalian hearts in opposing pat-
terns during cardiac development and
remodeling. Cardiac injury shifts this
ratio toward Myh7, with detrimental ef-
fects on cardiac functions and outcomes.Transcriptional and epigenetic regulation
govern the expression of Myh6 and
Myh7 genes (Hill and Olson, 2008), and
genetic mutations and altered expression
of these genes have been linked to car-
diac hypertrophy and other cardiomyopa-
thies (Ahmad et al., 2005). More recently,
miR-208a and miR-208b, encoded by in-
trons of Myh6 and Myh7, respectively,
have also been involved in the regulation
of a/b-MHC expression in pathological
cardiac hypertrophy (Callis et al., 2009;0, October 7, 2014 ª2014 Elsevier Inc. 555
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Figure 1. Regulation of Cardiac Gene Expression by Epigenetic Regulators and lncRNAs during Heart Development and Hypertrophy
(A) In cardiac progenitor cells, lncRNABraveheart functions as a decoy for PRC2 complex by binding to Suz12 to exclude the PRC2 complex from the promoter of
MesP1, a master cardiac transcription factor, thus leading to the activation of MesP1 and downstream cardiac specification transcription network. Similarly,
Fendrr, another cardiac lncRNA, associates with TrxG/MLL complex to regulate the activation of a set of cardiac specification genes in cardiac progenitor cells.
(B) In embryonic cardiomyocytes, where Brg1 expression remains relatively high, the involvement of lncRNAs is unclear. Mhrt may participate in the regulation of
Myh6 and Myh7 expression.
(C) In adult cardiomyocytes, Brg1 protein levels are low; thus the repression of Myh6 and Mhrt expression is released and Myh7 transcription is inhibited.
(D) Under cardiac stress, Brg1 is reactivated, which triggers the tipping of a mutual inhibitory balance between Mhrt and Brg1 complexes, resulting in the
reactivation of fetal gene program with high Myh7 expression and low Myh6 and Mhrt level in hypertrophic cardiomyocytes.
Cell Metabolism
Previewsvan Rooij et al., 2007). Han and col-
leagues now report that a long noncoding
RNA (lncRNA) transcript from the anti-
sense strand of the Myh7 locus functions
as a molecular switch in tipping the
balance between a- or b-MHC expres-
sion by regulating the Brg1-HDAC-PARP
chromatin remodeling complex (Han
et al., 2014).
Although lncRNAs lack functional open
reading frames, their critical roles in
various biological systems have been
increasingly recognized in recent years
(Batista and Chang, 2013). Perhaps the
most relevant examples of lncRNA func-
tion in cardiac lineage commitment would
be the recently identified Braveheart
and Fendrr (Grote et al., 2013; Klattenhoff
et al., 2013). Mechanistically, Braveheart
interacts with SUZ12, a component of
the polycomb-repressive complex 2556 Cell Metabolism 20, October 7, 2014 ª20(PRC2), to epigenetically activate the
expression of mesoderm posterior 1
(Mesp1), a master regulator of cardiovas-
cular progenitors. Interestingly, not only
can Fendrr bind to the PRC2 complex
and regulate its activity, it can also asso-
ciate with the TrxG/MLL complex to
control cardiac lineage commitment.
Previous work from Dr. Chang’s group
identified a Brg1-HDAC-PARP complex
that cooperatively controls the change
in the a/b-MHC ratio in failing hearts
(Hang et al., 2010). Han and colleagues
now describe a novel lncRNA, Myheart
(Mhrt), enriched in adult cardiomyocytes
and able to protect adult hearts from
pathological hypertrophy. The authors
initiated this elegant study by identifying
a cluster of alternatively spliced anti-
sense transcripts of the Myh7 gene.
Intriguingly, these lncRNAs, which are14 Elsevier Inc.spliced isoforms of Mhrt, appeared to
have a tight correlation with the Myh6/
Myh7 ratio during cardiac development
and in hypertrophic hearts. Indeed,
upon transverse aortic constriction
(TAC) in a mouse model of pathological
hypertrophy, cardiomyocytes showed a
progressive loss of Mhrt expression
along with the development of patholog-
ical hypertrophy. Remarkably, restoring
Mhrt expression to the prestress level
attenuated pathological hypertrophic re-
sponses and restored cardiac function,
demonstrating the cardioprotective role
of Mhrt in vivo.
ATP-dependent chromatin remodeling
complexes are important controllers of
chromatin dynamic structure, and their
biological specificity arises, at least partly,
from the combinatory assembly of the
complex (Ho and Crabtree, 2010). In order
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Previewsto uncover the molecular mechanism by
which Mhrt regulates Myh expression
and cardiac hypertrophy, Han et al. tested
whether the Brg1 chromatin remodeling
complex is responsible for the downregu-
lation of Mhrt expression in pathological
hypertrophy (Han et al., 2014). The au-
thors defined specific DNA elements
responsible for Brg1-mediated regulation
of Mhrt and Myh6. Perhaps the most
intriguing result of the paper is that Mhrt
can directly interact with the helicase
domain of Brg1 to regulate its occupancy
and activity, suggesting that Mhrt may
function as a decoy for the chromatin re-
modeler to prevent its occupancy on
target gene promoters. Thus, Han et al.
uncover a negative feedback loop be-
tween a lncRNA and the Brg1 chromatin
remodeling protein complex, providing a
molecular switch for fine-tuning the dy-
namic regulation of chromatin remodeling
complex function in the heart (Figure 1).
While this study unveils an important
novel lncRNA in cardiomyopathy, many
questions remain to be answered. For
example, it is still unclear how the binding
ofMhrt to the helicase domain of Brg1 can
modulate the assembly of the SWI/SNF
complex and how individual components
of this complex are specifically recruited.
Nor is it completely clear at this time
how a lncRNA can define the specificity
of such a regulatory complex to achieve
appropriate activation/repression of
target genes. More specifically, while the
Brg1 complex mediates Myh6 and Mhrt
inhibition, it also mediates the activation
of Myh7 in the same cell. It remains
elusive if the primary function of Mhrt is
to regulate Brg1-mediated Myh6 inhibi-
tion in cis or to regulate a plethora of
pathological hypertrophic genes in trans.
It should be pointed out that while mostof the functional studies conducted here
came from a gain-of-function approach,
a genetic loss-of-function approach for
Mhrt would be essential to establish its
biological function. It will also be inter-
esting to determine whether mutations in
Mhrt are associated with human cardio-
myopathy, especially hypertrophic car-
diomyopathy. Another fascinating fact
about Mhrt is that it is encoded partially
by the antisense strand of the Myh7
gene. Thus, to date, the DNA loci encod-
ing Myh6 and Myh7 have been found to
encompass not only major cardiac con-
tractile protein genes, but also micro-
RNAs (miR-208a and miR-208b) and
now lncRNA (Mhrt). It is amazing to
perceive how such rich biological in-
formation is incorporated into such a
condensed genomic region and raises
an interesting question not addressed in
the paper: are there physical and func-
tional interactions among mRNAs (Myh6,
Myh7), miRNAs (miR-208a, miR-208b),
and lncRNA (Mhrt) encoded by the Myh6
and Myh7 gene loci? Answers to these
questions will certainly reveal new mech-
anisms of how different coding and non-
coding RNAs arising from same locus
harmonize their functions, in cis or in
trans, during cardiac development and in
heart disease.
In summary, Han et al. identify Mhrt as
the first cardioprotective lncRNA in the
adult heart and also as the first lncRNA
regulating ATP-dependent chromatin re-
modeling complexes in vivo. Evidently,
we are still at the beginning of lncRNA
discovery; understanding their functional
roles and molecular mechanisms in a
variety of biological systems warrants
future investigation. Nevertheless, the
finding that an lncRNA directly regulates
chromatin remodeling and targets geneCell Metabolism 2expression undoubtedly offers great op-
portunities (and challenges) in developing
therapeutic interventions to treat cardio-
vascular diseases.ACKNOWLEDGMENTS
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